Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

Research

Vaccination strategies to enhance immunity in neonates

Protection may be further improved by integrating these approaches, namely vaccinating the neonate under the cover of vertically transferred maternal immunity

Research

Epidemiology and risk factors for recurrent severe lower limb cellulitis: a longitudinal cohort study

Severe lower leg cellulitis recurrences are frequent, and each episode increases the likelihood of subsequent recurrence and length of hospitalization

Research

Safety surveillance of influenza vaccine in pregnant women

Vaccination is the most effective strategy for preventing influenza infection in pregnancy.

Research

Multidrug-resistant tuberculosis in Western Australia, 1998-2012

Our objective was to describe the epidemiology, clinical features, health care resource use, treatment and outcomes of multidrug-resistant tuberculosis...

Research

Impact of CD14 promoter variants on measles vaccine responses and vaccine failure in children from Australia and Mozambique

Host genetics are likely to play a crucial role, particularly variants that alter key innate immune response genes.

Research

What do infectious diseases physicians do? A 2-week snapshot of inpatient consultative activities across Australia, New Zealand and Singapore

We performed a 2-week prospective survey of formal ID physician activities related to direct inpatient care, encompassing 53 hospitals throughout Australia,...

Research

Respiratory viral pathogens associated with lower respiratory tract disease among young children

Acute lower respiratory tract infections (ALRI) commonly result in fatal outcomes in the young children of Papua New Guinea (PNG).

Research

Immunogenicity and safety of measles-mumps-rubella and varicella vaccines coadministered

A pooled analysis was conducted of 1,257 toddlers who received a fourth dose of Haemophilus influenzae type b- Neisseria meningitidis serogroups C and...

Research

A randomized phase I study of the safety and immunogenicity

In this study of healthy adults aged 50-85 and 18-24 years, SA3Ag elicited a rapid and robust immune response and was well tolerated, with no notable safety...